FundedIQ
Biotechnology

NeuroCytonix: Funding, Investors & Team (Sep 2026)

NeuroCytonix is a company dedicated to biomedical technologies, which specializes in the creation and regeneration of tissues. They provide advanced medical biotechnology that is improving the way non-progressive neurodegenerative disorders are treated, including stroke, spinal cord injury, cerebral palsy, and traumatic brain injury.

www.neurocytonix.com LinkedIn Rockville, United States 11-50 employees
Total raised
$4.0M
Rounds
1
Latest
Undisclosed round
Apr 2023

NeuroCytonix has raised $4.0M across 1 funding round on record, the most recent an undisclosed round of $4.0M announced in Apr 2023.

That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

NeuroCytonix Company Profile and Key Stats

Total funding raised
$4.0M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$4.0M in Apr 2023
Employees
11-50
reported band
Headquarters
Rockville, United States

Latest funding round on record: Apr 2023.

NeuroCytonix Funding Rounds

Date
Round
Amount
Undisclosed round
$4.0M

NeuroCytonix Founders and Leadership Team

Name
Role
Contact
J Roberto Trujillo
CEO

No contact details are on record for this team yet.

NeuroCytonix Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M

NeuroCytonix's latest round of $4.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like NeuroCytonix in Biotechnology and Rockville

Companies Similar to NeuroCytonix

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

NeuroCytonix Funding FAQs

What does NeuroCytonix do?

NeuroCytonix is a company dedicated to biomedical technologies, which specializes in the creation and regeneration of tissues. They provide advanced medical biotechnology that is improving the way non-progressive neurodegenerative disorders are treated, including stroke, spinal cord injury, cerebral palsy, and traumatic brain injury.

How much funding has NeuroCytonix raised?

NeuroCytonix has raised $4.0M across 1 round on record. The most recent is an undisclosed round of $4.0M announced in Apr 2023.

When did NeuroCytonix last raise funding?

NeuroCytonix's most recent funding round on record is an undisclosed round of $4.0M, announced in Apr 2023.

Who is the CEO of NeuroCytonix?

J Roberto Trujillo is listed as CEO at NeuroCytonix.

Where is NeuroCytonix headquartered?

NeuroCytonix is based in Rockville, Maryland, United States.

How many employees does NeuroCytonix have?

NeuroCytonix is in the 11-50 employee band.

How does NeuroCytonix's funding compare to other Biotechnology startups?

NeuroCytonix's latest round of $4.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's NeuroCytonix Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NeuroCytonix is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.